# US 2026/0199368 A1 · Oromucosal delivery system containing remimazolam

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0199368 A1
- Document ID: US20260199368A1
- Status: Published application
- Kind: A1
- Application number: 19/136,442
- Filed: 2023-12-14
- Published: 2026-07-16
- Earliest claimed: 2022-12-16
- Applicants: Lts Lohmann Therapie-Systeme AG; Paion UK Ltd.
- Inventors: Stefan LORSCHEIDT; Eva-Marie PRINZ; Elke KLEIN; Marco EMGENBROICH; Marija PESIC; Oliver KOPS; Thomas STÖHR
- Web page: https://patentgrep.com/patent/US20260199368A1

## CPC

- A61K 9/7007: {Drug-containing films, membranes or sheets (A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence)}
- A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/38: Cellulose; Derivatives thereof
- B65D 75/20: in sheets or blanks doubled around contents and having their opposed free margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
- B65D 81/267: {the absorber being in sheet form}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B65D: CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES

## Abstract

The present invention relates to oromucosal delivery systems for the transmucosal administration of an active agent comprising an active agent-containing layer comprising remimazolam, such remimazolam oromucosal delivery systems for producing sedation, a method of producing sedation comprising applying such remimazolam oromucosal delivery systems, and processes of manufacture of such remimazolam oromucosal delivery systems.

## Claims

### Claim 1

Oromucosal delivery system for the transmucosal delivery of an active agent, comprising
an active agent-containing layer comprising:
i) remimazolam, a pharmaceutically acceptable salt, or any other form thereof, as active agent and
ii) a film-forming agent,
wherein the oromucosal delivery system is in the form of a film.

### Claim 2 (depends on 1)

Oromucosal delivery system according to claim 1,
wherein the active agent-containing layer comprises
at least 20 wt-%, at least 25 wt-% or at least 30 wt-% of the active agent, and/or
less than or equal to 60 wt-%, less than or equal to 55 wt-%, or less than or equal to 50 wt-% of the active agent, and/or
from 20 to 60 wt-%, from 25 to 55 wt-% or from 30 to 50 wt-% of the active agent.

### Claim 3 (depends on 1, 2)

Oromucosal delivery system according to claim 1 or 2,
wherein the active agent is remimazolam besylate or remimazolam tosylate.

### Claim 4 (depends on 1, 2, 3)

Oromucosal delivery system according to any one of claims 1 to 3 comprising an active agent-containing layer comprising:
i) remimazolam, a pharmaceutically acceptable salt, or any other form thereof, as active agent,
ii) a film-forming agent, and
iii) a plasticizer.

### Claim 5 (depends on 1, 2, 3, 4)

Oromucosal delivery system according to any one of claims 1 to 4,
wherein the plasticizer is polyethylene glycol or a polyvinyl alcohol-polyethylene glycol grafted copolymer, and/or
wherein the film-forming agent is a polymer selected from the group consisting of polyvinyl alcohol, polyvinyl alcohol-polyethylene glycol grafted copolymers, polyethylene oxides, polyvinylpyrrolidone, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft co-polymer, polyethylene glycols, hydroxypropylmethyl cellulose or any mixture thereof.

### Claim 6 (depends on 1, 2, 3, 4, 5)

Oromucosal delivery system according to any one of claims 1 to 5,
wherein the film-forming agent is a polyvinyl alcohol having a molecular weight in the range from 10,000 to 250,000, or a mixture of two or more polyvinyl alcohols, each having a molecular weight in the range from 10,000 to 250,000.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

Oromucosal delivery system according to any one of claims 1 to 6,
wherein the active agent-containing layer further comprises one or more excipients selected from the group consisting of sweeteners, flavoring agents, antioxidants and pH adjusting agents, and/or
wherein the active agent-containing layer does not comprise a pH adjusting agent.

### Claim 8 (depends on 7)

Oromucosal delivery system according to claim 7,
wherein the sweeteners are selected from the group consisting of sucralose, acesulfame potassium, N—[N-[3-(3-Hydroxy-4-methoxyphenyl)propyl]-α-L-aspartyl]-L-phenylalanin-1-methylester, N—[N-(3,3-Dimethylbutyl)-L-α-aspartyl]-L-phenylalanine 1-methyl ester, aspartame, thaumatine, and/or
wherein the flavoring agents are natural or synthetic flavoring agents such as flavoring compositions selected from the group consisting of a combination of Linalool, Alpha Pinene, Citral, Delta 3 Carene, Beta Pinene and Myrcene, and a combination of Geranyle Acetate, Vanillin, Limonene and Allyl hexanoate.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

Oromucosal delivery system according to any one of claims 1 to 8,
wherein the active agent-containing layer is in the form of a flexible foam or a flexible monolithic film.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

Oromucosal delivery system according to any one of claims 1 to 9,
wherein the oromucosal delivery system is in the form of a film, and
wherein, when a sample film of the oromucosal delivery system with a size of 5.75 cm2 is dissolved in 5 mL of artificial saliva or of 0.9% NaCl solution, the pH of the resulting solution as measured by a pH electrode ranges from pH 3.0 to pH 3.7.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

Oromucosal delivery system according to any one of claims 1 to 10, wherein the oromucosal delivery system provides, after single administration to the buccal mucosa of the oral cavity of a human subject,
a bioavailability of greater than 10% based on cmax or of greater than 20% based on AUC,
a cmax of equal to or greater than 0.3 μg/mL, and/or
a tmax of 10 to 40 min or of 10 to 20 min.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

Oromucosal delivery system according to any one of claims 1 to 11 for use in producing sedation, producing hypnosis, producing anxiolysis, producing muscle relaxation, the treatment of convulsions or the induction of amnesia for perioperative events.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A pharmaceutical product comprising
a packaging, and
one or more unit doses of the oromucosal delivery system according to any one of claims 1 to 11.

### Claim 14 (depends on 13)

Pharmaceutical product according to claim 13,
wherein the packaging is in the form of a pouch,
wherein the pouch comprises one or more desiccant(s).

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

Process of manufacture of an active agent-containing layer as defined in any one of claims 1 to 11 comprising the steps of:
i. combining at least (i) remimazolam, a pharmaceutically acceptable salt, or any other form thereof, as active agent, and (ii) a film-forming agent to obtain a mixture; and
ii. forming the active agent-containing layer.

### Claim 16 (depends on 15)

Process of manufacture according to claim 15,
wherein the process is a foam forming process comprising the steps of:
i. dispersing or dissolving the active agent in an aqueous solution of the film-forming agent with or without further excipients to obtain a coating composition, and
ii. a. foaming the coating composition to obtain a foam coating composition;
b. coating the foam coating composition on a coating substrate; and
c. drying the laminate segments in a drying oven to obtain the active agent-containing layer in the form of a foam.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 16)

Process of manufacture of an oromucosal delivery system comprising an active agent-containing layer comprising (i) remimazolam, a pharmaceutically acceptable salt, or any other form thereof, as active agent, and (ii) a film-forming agent according to any one of claims 1 to 11 comprising the steps of:
i. combining at least the active agent and a film-forming agent to obtain a mixture; and
ii. forming the active agent-containing layer
as defined in claim 15 or 16.

### Claim 18 (depends on 17)

Oromucosal delivery system obtainable by a process according to claim 17.

### Claim 19 (depends on 1)

Oromucosal delivery system according to claim 1, wherein the active agent-containing layer comprises
i) 55 to 60 wt-% of remimazolam besylate;
ii) 10 to 15 wt-% of polyvinyl alcohol as film-forming agent,
iii) 30 to 35 wt-% of a polyvinyl alcohol-polyethylene glycol grafted copolymer,
iv) from 0.05 to 1 wt-% of one or more sweeteners, and
v) from 0.5 to 2 wt-% of a flavoring agent
wherein
the area weight of the active agent-containing layer is less than or equal to 200 g/m2.

### Claim 20 (depends on 1)

Oromucosal delivery system according to claim 1, wherein the active agent-containing layer comprises
i) 55 to 60 wt-% of remimazolam besylate;
ii) 15 to 20 wt-% of polyvinyl alcohol as film-forming agent
iii) 20 to 26 wt-% of a polyvinyl alcohol-polyethylene glycol grafted copolymer,
iv) from 0.05 to 1 wt-% of one or more sweeteners, and
v) from 0.5 to 2 wt-% of a flavoring agent
wherein
the area weight of the active agent-containing layer is less than or equal to 200 g/m2.
